Semaglutide, a glucagon like peptide-1 (GLP-1) receptor agonist, is accessible as monotherapy in both of those subcutaneous as well as oral dosage kind (1st accepted oral GLP-1 receptor agonist). It's been accredited as a 2nd line cure choice for greater glycaemic Handle in variety two diabetes and now underneath scrutiny https://alany110itd2.popup-blog.com/profile